These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27113274)

  • 1. Statins in Cirrhosis: The Magic Pill?
    Malizia G; D'Amico G
    Hepatology; 2016 Jun; 63(6):2047-9. PubMed ID: 27113274
    [No Abstract]   [Full Text] [Related]  

  • 2. Statins and portal hypertension: A tale of two models.
    Arab JP; Shah VH
    Hepatology; 2016 Jun; 63(6):2044-7. PubMed ID: 27015447
    [No Abstract]   [Full Text] [Related]  

  • 3. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.
    Garcia-Tsao G; Lim JK;
    Am J Gastroenterol; 2009 Jul; 104(7):1802-29. PubMed ID: 19455106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cirrhosis as new indication for statins.
    Bosch J; Gracia-Sancho J; Abraldes JG
    Gut; 2020 May; 69(5):953-962. PubMed ID: 32139553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
    Deng D; Liao MS; Qin JP; Li XA
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):232-6. PubMed ID: 16698582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.
    Corpechot C; Carrat F; Poujol-Robert A; Gaouar F; Wendum D; Chazouillères O; Poupon R
    Hepatology; 2012 Jul; 56(1):198-208. PubMed ID: 22271046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
    Vargas JI; Arrese M; Shah VH; Arab JP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of statins in the diseases of the liver.
    Janicko M; Drazilova S; Pella D; Fedacko J; Jarcuska P
    World J Gastroenterol; 2016 Jul; 22(27):6201-13. PubMed ID: 27468210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunological course in two patients with idiopathic portal hypertension.
    Tokushige K; Tsuchiya N; Yamaguchi N; Taniai M; Hashimoto E; Yamauchi K; Hayashi N
    J Gastroenterol; 2002; 37(12):1086-9. PubMed ID: 12522545
    [No Abstract]   [Full Text] [Related]  

  • 14. The Safety and Benefit of Statins in Liver Cirrhosis: a Review.
    Souk K; Al-Badri M; Azar ST
    Exp Clin Endocrinol Diabetes; 2015 Nov; 123(10):577-80. PubMed ID: 26600051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Maintenance" treatment for patients with cirrhosis related to hepatitis C.
    Gross JB
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):427-9. PubMed ID: 17445750
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension.
    Krasinskas AM; Eghtesad B; Kamath PS; Demetris AJ; Abraham SC
    Liver Transpl; 2005 Jun; 11(6):627-34; discussion 610-1. PubMed ID: 15915493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis.
    Pind ML; Bendtsen F; Kallemose T; Møller S
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):948-54. PubMed ID: 27172450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of ACE inhibitor (ednit) on portal hemodynamics in patients with hepatic cirrhosis].
    Postnikova TN; Larina EA; Berdnikov SV; Serov NA
    Klin Med (Mosk); 1999; 77(12):46-7. PubMed ID: 10684217
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.